# US 2019/0293647 A1 · Circulating astrocytes and mfsd2a as biomarkers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0293647 A1
- Document ID: US20190293647A1
- Status: Published application
- Kind: A1
- Application number: 16/431,559
- Filed: 2019-06-04
- Published: 2019-09-26
- Earliest claimed: 2017-02-19
- Assignees: Sheng-He Huang; Alec Chan
- Inventors: Sheng-He Huang
- Web page: https://patentgrep.com/patent/US20190293647A1

## CPC

- G01N 33/56966: {Animal cells}
- A61K 45/00: Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K 31/13: Amines {(A61K31/04 takes precedence)}
- G01N 2333/70571: for neuromediators, e.g. serotonin receptor, dopamine receptor
- G01N 2800/2871: Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
- G01N 2800/50: Determining the risk of developing a disease
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention provides the use of circulating astrocytes (cAstr) and the Major Facilitator Superfamily Domain containing Protein 2a (Mfsd2a) as biomarkers, and their combined use with other related circulating markers (cBMEC and EPC) in early detection and diagnosis of cerebrovascular diseases (CVD) or central nervous system (CNS) disorders.

## Claims

### Claim at position 1

1-19. (canceled)

### Claim 20

A method for diagnosing a traumatic brain injury, the method comprising:
(a) obtaining a peripheral blood sample from a human subject;
(b) using a first magnetic bead to concentrate circulating brain microvascular endothelial cells from the peripheral blood sample;
(c) using a second magnetic bead to isolate circulating brain microvascular endothelial cells containing major facilitator superfamily domain-containing protein 2,
(d) staining the isolated circulating brain microvascular endothelial cells with a conjugated antibody;
(e) counting the number of the stained brain microvascular endothelial cells; and
(f) determining that the human subject has traumatic brain injury when a density of the circulating brain microvascular endothelial cells is greater than 90 count per milliliter.

### Claim 21 (depends on 20)

The method of claim 20, wherein the first magnetic bead is a lectin based.

### Claim 22 (depends on 20)

The method of claim 20, wherein the conjugated antibody is a FITC conjugated CD146 antibody.

### Claim 23

A method for diagnosing a brain microbial infection, the method comprising:
(a) obtaining a peripheral blood sample from a human subject;
(b) using a first magnetic bead to concentrate circulating brain microvascular endothelial cells from the peripheral blood sample;
(c) using a second magnetic bead to isolate circulating brain microvascular endothelial cells containing major facilitator superfamily domain-containing protein 2,
(d) staining the isolated circulating brain microvascular endothelial cells with a conjugated antibody;
(e) counting the number of the stained brain microvascular endothelial cells; and
(f) determining that the human subject has brain microbial infection when a density of the circulating brain microvascular endothelial cells is greater than 90 count per milliliter.

### Claim 24 (depends on 23)

The method of claim 23, wherein the first magnetic bead is a lectin based.

### Claim 25 (depends on 23)

The method of claim 23, wherein the conjugated antibody is a FITC conjugated CD146 antibody.

### Claim 26

A method for diagnosing blood brain barrier injury, the method comprising:
(a) obtaining a peripheral blood sample from a human subject;
(b) using a first magnetic bead to concentrate circulating brain microvascular endothelial cells from the peripheral blood sample;
(c) using a second magnetic bead to isolate circulating brain microvascular endothelial cells containing major facilitator superfamily domain-containing protein 2,
(d) staining the isolated circulating brain microvascular endothelial cells with a conjugated antibody;
(e) counting the number of the stained brain microvascular endothelial cells; and
(f) determining that the human subject suffers an injury to his blood brain barrier when a density of the circulating brain microvascular endothelial cells is greater than 90 count per milliliter.
